---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055872"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T10:43:19.212247+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crinetics to present initial atumelnant Phase 2 data in CAH and Cushing's at ENDO 2024

## Summary
- Five abstracts, four late-breaking, to be presented at ENDO 2024 (June 1-4, Boston).
- Initial Phase 2 TouCAHn data: atumelnant shows rapid, profound reductions in androstenedione and 17-hydroxyprogesterone in classic congenital adrenal hyperplasia.
- Phase 1b/2a data on atumelnant in ACTH-dependent Cushing's shows first evidence of rapid, sustained cortisol reductions.
- Phase 3 PATHFNDR-2 paltusotine data in medically untreated acromegaly patients to be presented; PATHFNDR-1 patient-reported symptoms and long-term safety also featured.
- Crinetics plans to submit paltusotine NDA later in 2024; CEO cites major milestone for pipeline.

## SEC filing metadata
- accession: 0000950170-24-055872
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017024055872/0000950170-24-055872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017024055872/crnx-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055872
- JSON: https://secwatch.observer/filing/0000950170-24-055872.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.